Wheatgrass Juice Powder Shows Anticancer Potential Against Prostate and Lung Cancer Cells in Lab Study
Karakılçık wheatgrass juice powder killed prostate and lung cancer cells in the lab, with dose-dependent antiproliferative effects across four human cell lines, according to a study published in Scientific Reports on January 27, 2026.
The work paired lab experiments with computer simulations of how the powder’s compounds bind to cancer-driving proteins.
Key Clinical Takeaways:
- Wheatgrass juice powder from the Karakılçık wheat variety showed antiproliferative effects on prostate cancer (PC-3), lung carcinoma (A549), non-small cell lung cancer (H1975) and normal epithelial (BEAS-2B) cells in vitro.
- Seven phenolic compounds, including apigenin and quercetin, showed strong binding affinity in molecular docking against cancer-related targets, with binding energies reaching −9.6 kcal/mol.
- Computer modeling suggests good oral bioavailability and low estimated toxicity, but the researchers themselves state further studies are required to support clinical validity.
The study, led by Aliye Demet Demirag, Bilge Bicak and Reyhan Akpinar with four co-authors, examined a wheatgrass variety grown in the Gaziantep region of southeastern Turkey, an area the paper describes as an important grain-production center whose semiarid climate and agricultural heritage shape the variety’s phytochemical profile. The Karakılçık genotype is described in the study as genetically conserved and phytochemically distinct.
Why it matters: cancer remains a leading cause of death worldwide. According to the study’s own figures, citing the World Health Organization GLOBOCAN 2020 report, 19.3 million new cancer cases were detected globally in 2020, resulting in approximately 10 million deaths. The paper frames that burden as a persistent unmet need for novel, safe and mechanistically effective therapeutic approaches.
Four cell lines, one dose-dependent pattern
The cytotoxicity work tested wheatgrass juice powder against the human prostate cancer cell line PC-3, the human lung carcinoma line A549, the non-small cell lung cancer line H1975 and the epithelial line BEAS-2B. The study reported dose-dependent antiproliferative effects on all of them, meaning the growth-suppressive effect increased with concentration.
That breadth is notable because the three cancer lines represent different disease biology — prostate adenocarcinoma and two lung cancer models — while BEAS-2B served as a non-cancer comparison. The paper does not report selectivity ratios between cancer and normal cells, a figure clinicians would typically want before drawing treatment implications.
Seven compounds, five cancer targets
To probe mechanism, the researchers identified seven phenolic compounds in the powder — apigenin, caffeic acid, catechin, coumarin, ellagic acid, esculetin and quercetin — and ran molecular docking analyses against cancer-related targets including the androgen receptor, PSMA, mTOR, Akt1 and PI3K. Some major compounds showed high binding affinity and could inhibit cancer-related signaling pathways, the study reports.
One hundred nanosecond molecular dynamics simulations on selected phytochemical–target complexes confirmed structural stability, binding persistence and favorable dynamic behavior of the most promising interactions under physiological conditions, per the study. In silico ADMET analysis, which estimates absorption, distribution, metabolism, elimination and toxicity, showed good oral bioavailability and a low estimated toxicity profile.
The same study, indexed by Europe PMC, adds detail on binding energies for four further anticancer targets: the estrogen receptor, EGFR, IKK-β and CXCR-4. Apigenin showed the strongest and most consistent profile, ranging from −8.4 to −9.6 kcal/mol, with its −9.6 kcal/mol binding to IKK-β suggesting effective inhibition of that enzyme, a key regulator of the NF-κB pathway. Quercetin, catechin and ellagic acid followed close behind.
| Compound | EGFR (kcal/mol) | Human IKK-β (kcal/mol) | CXCR4 (kcal/mol) |
|---|---|---|---|
| Apigenin | −8.9 | −9.6 | −8.4 |
| Quercetin | −8.9 | −9.3 | −8.4 |
| Catechin | −8.5 | −9.1 | −7.9 |
| Ellagic acid | −8.8 | −9.4 | −9.2 |
| Caffeic acid | −6.2 | −6.8 | −6.6 |
| Coumarin | −6.1 | −6.8 | −7.5 |
The docking work also carried a formulation angle. Taste activity estimations determined the potential bitter, sweet and sour profiles of the major compounds, an evaluation the study presents to support the development of oral supplement formulations. That detail signals the team’s intent: a supplement candidate, not an oncology drug, at least for now.
Where the evidence stops
Every result in the study is preclinical. The antiproliferative effects come from cell cultures; the binding affinities come from software models; the ADMET figures are predictions, not measured pharmacokinetics in humans or animals. The study’s own conclusion says wheatgrass juice powder “shows potential as a natural therapeutic agent against prostate and lung cancers” and that further studies are required to support its clinical validity.
That gap between docking prediction and clinical effect is well documented in natural-product research: a binding energy of −9.6 kcal/mol in silico does not translate into a tumor response in a patient.
Patients with prostate or lung cancer considering wheatgrass or other supplements should discuss them with their treating oncologist, since supplements can interact with standard-of-care therapies and are not substitutes for evidence-based treatment. A board-certified oncologist or a registered dietitian working with an oncology team can review contraindications and interactions before any supplement is added to a regimen.
What would come next
The logical sequence from here, based on what the paper reports, is confirmatory work the authors themselves flag: additional studies to establish clinical validity. That would typically mean animal pharmacokinetics and, eventually, controlled human testing — none of which the study includes. The taste-profile analysis suggests the near-term output is more likely an oral supplement formulation than a prescription therapeutic.
The study was published open access under a Creative Commons CC BY-NC-ND 4.0 licence, per the Europe PMC record.
For now, the finding sits where most natural-product cancer research does: an intriguing dose-dependent signal in cell lines, a plausible molecular mechanism on paper, and a long road between a Gaziantep wheat field and an oncology clinic.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Keep reading
- Flu Vaccination Prevents Thousands of Hospitalizations Among Seniors in France
- WhatsApp Launches Own Cloud Backup Storage for Android Beta Testers, Offers 2 GB Free Tier
- Mouse Study: mRNA Vaccine Boosts T Cells to 80% in Brain Tumor Therapy (newsy-today.com)
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)